{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:09:01Z","timestamp":1792271341546,"version":"4.4.0"},"reference-count":24,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Cancer Control"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Among advanced multiple myeloma (MM) patients, B-cell maturation antigen (BCMA) specific targets like Belantamab Mafodotin (belamaf) and CAR T-cell therapies have been shown to improve clinical outcomes, but at significant costs. To compare the expected costs per quality-adjusted life years (QALYs) gained among a hypothetical cohort of triple refractory MM patients treated with one of three BCMA-directed therapies: (1) idecabtagene vicleucel (ide-cel), (2) ciltacabtagene autoleucel (cilta-cel), and (3) belamaf for up to 20\u00a0months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this cost-effectiveness analysis, we built a Monte Carlo Markov Chain microsimulation model using estimates and parameters from the evidence on MM treatment for 10\u00a0000 hypothetical patients between the ages for 40 and 80. We assigned expected years of life remaining and made varying assumptions about survival beyond 5\u00a0years<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>We predicted total cost of treatment for CAR-T therapy to be six times greater than for belamaf, but the QALYs gained from treatment are 6 to 8 times greater. Ide-cel was weakly dominated by cilta-cel and our base-case incremental cost effectiveness ratio (ICER) comparing cilta-cel with belamaf was $109,497 per QALY gained, averaging $123,618 in probabilistic sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These findings hinge on the assumption of longer-term survival but suggest that the use of CAR-T therapy is approaching standard ICER thresholds.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/10732748221142945","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T03:07:41Z","timestamp":1674011261000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":28,"title":["Cost-Effectiveness Analysis of CAR T-Cell Therapies vs Antibody Drug Conjugates for Patients with Advanced Multiple Myeloma"],"prefix":"10.1177","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1577-4917","authenticated-orcid":false,"given":"Kandice A.","family":"Kapinos","sequence":"first","affiliation":[{"name":"Peter O\u2019Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA"},{"name":"Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA"},{"name":"RAND Corporation, Arlington, VA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Hu","sequence":"additional","affiliation":[{"name":"Peter O\u2019Donnell Jr. School of Public Health, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigar","family":"Trivedi","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Texas Southwestern Medical Center, Dallas 75390-9096, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Praveen Ramakrishnan","family":"Geethakumari","sequence":"additional","affiliation":[{"name":"Division of Hematologic Malignancies and Cellular Therapy, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Kansagra","sequence":"additional","affiliation":[{"name":"Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX, USA"},{"name":"Division of Hematologic Malignancies and Cellular Therapy, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,1,18]]},"reference":[{"key":"bibr1-10732748221142945","volume-title":"SEER Cancer Stat Facts: Myeloma","author":"National Cancer Institute","year":"2017"},{"key":"bibr2-10732748221142945","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01471-3"},{"key":"bibr3-10732748221142945","volume-title":"Anti B-Cell Maturation Antigen CAR T-Cell and Antibody Conjugate Therapy for Heavily Pre-treated Relapsed and Refractory Multiple Myeloma: FInal Evidence Report","author":"Lee SJ","year":"2021"},{"key":"bibr4-10732748221142945","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30788-0"},{"key":"bibr5-10732748221142945","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0435-7"},{"key":"bibr6-10732748221142945","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024850"},{"key":"bibr7-10732748221142945","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1913143"},{"key":"bibr8-10732748221142945","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00933-8"},{"key":"bibr9-10732748221142945","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.2072"},{"key":"bibr10-10732748221142945","volume-title":"Value Assessment Framework","author":"Institute for Clinical Economic Review","year":"2020"},{"key":"bibr11-10732748221142945","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.12195"},{"issue":"12","key":"bibr12-10732748221142945","first-page":"1","volume":"14","author":"Nikolaou A","year":"2021","journal-title":"Expet Rev Hematol"},{"key":"bibr13-10732748221142945","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-299487"},{"issue":"4","key":"bibr14-10732748221142945","first-page":"204","volume":"8","author":"Roy A","year":"2015","journal-title":"Am Health Drug Benefits"},{"key":"bibr15-10732748221142945","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1769109"},{"key":"bibr16-10732748221142945","doi-asserted-by":"crossref","unstructured":"Hari P, Nguyen A, McGarvey N, et al. Healthcare resource utilization and cost of cytokine release syndrome and neurotoxicity in patients with relapsed and refractory multiple myeloma receiving the bcma-directed chimeric antigen receptor t cell therapy idecabtagene vicleucel (ide-cel, bb2121) in the karmma trial. Inn: Paper presented at: 62nd American Society of Hematology Annual Meeting and Exposition202, December 5, 2020,","DOI":"10.1200\/JCO.2020.38.29_suppl.61"},{"key":"bibr22-10732748221142945","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2010.304"},{"key":"bibr23-10732748221142945","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136677"},{"key":"bibr24-10732748221142945","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.29_suppl.61"},{"key":"bibr25-10732748221142945","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.138"},{"key":"bibr17-10732748221142945","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2013.02.010"},{"key":"bibr18-10732748221142945","volume-title":"Amua: An open source modeling framework","author":"Ward ZJ","year":"2019"},{"key":"bibr20-10732748221142945","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1405158"},{"key":"bibr21-10732748221142945","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0561-2"}],"container-title":["Cancer Control"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748221142945","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/10732748221142945","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/10732748221142945","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T14:23:21Z","timestamp":1777386201000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/10732748221142945"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":24,"alternative-id":["10.1177\/10732748221142945"],"URL":"https:\/\/doi.org\/10.1177\/10732748221142945","relation":{"has-review":[{"id-type":"doi","id":"10.1177\/10732748221142945\/v1\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748221142945\/v2\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748221142945\/v1\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748221142945\/v2\/review1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748221142945\/v2\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748221142945\/v3\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748221142945\/v1\/decision1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748221142945\/v3\/response1","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748221142945\/v3\/review2","asserted-by":"object"},{"id-type":"doi","id":"10.1177\/10732748221142945\/v3\/review1","asserted-by":"object"}]},"ISSN":["1073-2748","1526-2359"],"issn-type":[{"value":"1073-2748","type":"print"},{"value":"1526-2359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"10732748221142945"}}